Shares of Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) hit a new 52-week low on Thursday . The stock traded as low as $6.05 and last traded at $6.22, with a volume of 247043 shares trading hands. The stock had previously closed at $6.58. Wall Street Analyst Weigh In Several research analysts have weighed […]
Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) insider Joan Nickerson sold 1,514 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $8.24, for a total transaction of $12,475.36. Following the completion of the transaction, the insider now owns 8,659 shares in […]
Verve Therapeutics (NASDAQ:VERV – Get Free Report)‘s stock had its “outperform” rating reissued by Royal Bank of Canada in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $35.00 target price on the stock. Royal Bank of Canada’s price objective indicates a potential upside of 89.70% from the company’s previous […]
Verve Therapeutics (NASDAQ:VERV – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.14, Briefing.com reports. The company had revenue of $5.14 million during the quarter, compared to analyst estimates of $3.95 million. Verve Therapeutics had a […]